热休克蛋白90在乳腺癌发生发展及治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2022.04.017

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (4): 381-385.doi: 10.11904/j.issn.1002-3070.2022.04.017

热休克蛋白90在乳腺癌发生发展及治疗中的研究进展

宗禹萱综述, 庞达审校

哈尔滨医科大学附属肿瘤医院乳腺一病区(哈尔滨 150081)

收稿日期:2021-06-30 修回日期:2021-11-29 出版日期:2022-08-28 发布日期:2022-08-29
通讯作者: 庞达,E-mail:pangdasir@163.com
作者简介:宗禹萱,女,(1994-),硕士,住院医师,从事乳腺良恶性肿瘤方面的研究。

Research progress of heat shock protein 90 in the occurrence,development and treatment of breast cancer

ZONG Yuxuan, PANG Da

The 1st Ward of Mammary Gland,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2021-06-30 Revised:2021-11-29 Online:2022-08-28 Published:2022-08-29

摘要/Abstract

摘要： 乳腺癌已成为发病率最高的恶性肿瘤之一。热休克蛋白90(HSP90)被称为分子伴侣,其在合成多肽、控制蛋白数量、蛋白折叠、调控蛋白活性和蛋白降解过程中发挥重要作用。HSP90可调节细胞生长、粘附、侵袭、转移、血管生成和细胞凋亡等,在乳腺癌发展过程中起重要的作用。HSP90抑制剂在抵抗肿瘤生长和抑制侵袭方面发挥积极作用,成为一种新的治疗手段。本文就HSP90与乳腺癌的关系,以及HSP90抑制剂介导的乳腺癌治疗新模式进行阐述。

关键词: 乳腺癌, 热休克蛋白90, 热休克蛋白90抑制剂

Abstract: Breast cancer has become one of the malignant tumors highest incidence.Heat shock protein 90(HSP90)is called a molecular chaperone,which plays an important role in the synthesis of peptide,control of protein quantity,protein folding,activity and degradation.HSP90 can regulate cell growth,adhesion,invasion,metastasis,angiogenesis and apoptosis,etc,and plays an important role in the development of breast cancer.HSP90 inhibitors play an active role in resisting tumor growth and inhibiting invasion,becoming a new treatment method.This article further elucidates the relationship between HSP90 and breast cancer,and the new mode of breast cancer treatment mediated by HSP90 inhibitors.

Key words: Breast cancer, Heat shock protein 90, Heat shock protein 90 inhibitor

中图分类号:

R737.9

宗禹萱, 庞达. 热休克蛋白90在乳腺癌发生发展及治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 381-385.

ZONG Yuxuan, PANG Da. Research progress of heat shock protein 90 in the occurrence,development and treatment of breast cancer[J]. Journal of Practical Oncology, 2022, 36(4): 381-385.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/381

参考文献

1 Zeng L,Li W,Chen CS.Breast cancer animal models and applications[J].Zool Res,2020,41(5):477-494.
2 Barzaman K,Karami J,Zarei Z.Breast cancer:biology,biomarkers,and treatments[J].Int Immunopharmacol,2020,84:106535.
3 Graner MW.HSP90 and immune modulation in cancer[J].Adv Cancer Res,2016,29:191-224.
4 Barna J,Csermely P,Vellai T.Roles of heat shock factor 1 beyond the heat shock response[J].Cell Mol Life Sci,2018,75(16):2897-2916.
5 Pearl LH,Prodromou C.Structure and mechanism of the Hsp90 molecular chaperone machinery[J].Annu Rev Biochem,2006,75:271-294.
6 Kampinga HH,Hageman J,Vos MJ,et al.Guidelines for the nomenclature of the human heat shock proteins[J].Cell Stress Chaperones,2009,14(1):105-111.
7 Dzaman-Serafin S.Heat shock proteins and their characteristics[J].Pol Merkur Lekarski,2005,19(110):215-219.
8 Schopf FH,Biebl MM,Buchner J.The HSP90 chaperone machinery[J].Nat Rev Mol Cell Biol,2017,18(6):345-360.
9 Li T,Kang G,Wang T,et al.Tumor angiogenesis and anti-angiogenic gene therapy for cancer[J].Oncol Lett,2018,16(1):687-702.
10 Zhang PC,Liu X,Li MM.AT-533,a novel Hsp90 inhibitor,inhibits breast cancer growth and HIF-1/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo[J].Biochem Pharmacol,2020,172:113771.
11 Jafari A,Rezaei-Tavirani M,Farhadihosseinabadi B,el at.HSP90 and Co-chaperones:impact on tumor progression and prospects for molecular-targeted cancer therapy[J].Cancer Invest,2020,38(5):310-328.
12 Bai J,Zhou G,Qiu Y,et al.HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells[J].Cancer Sci,2017,108(6):1177-1184.
13 Calderwood SK,Gong J.Heat shock proteins promote cancer:it's a protection racket[J].Trends Biochem Sci,2016,41(4):311-323.
14 Costa TEMM,Raghavendra NM,Penido C,et al.Natural heat shock protein 90 inhibitors in cancer and inflammation[J].Eur J Med Chem,2020,189:112063.
15 Cheng Q,Chang JT,Geradts J,et al.Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer[J].Breast Cancer Res,2012,14(2):62.
16 Barrott JJ,Haystead TA.Hsp90.an unlikely ally in the war on cancer[J].FEBS J,2013,280(6):1381-1396.
17 Crouch BT,Gallagher J,Wang R,et al.Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer[J].Sci Rep,2019,9(1):3461.
18 Gao C,Peng YN,Wang HZ,et al.Inhibition of heat shock protein 90 as a novel platform for the treatment of cancer[J].Curr Pharm Des,2019,25(8):849-855.
19 García-Becerra R,Santos N,Díaz L,et al.Mechanisms of resistance to endocrine therapy in breast cancer:focus on signaling pathways,miRNAs and genetically based resistance[J].Int J Mol Sci,2012,14(1):108-145.
20 Schiff R,Massarweh S,Shou J,et al.Breast cancer endocrine resistance:how growth factor signaling and estrogen receptor coregulators modulate response[J].Clin Cancer Res,2003,9(1 Pt 2):447-454.
21 Krämer OH,Mahboobi S,Sellmer A,et al.Drugging the HDAC6-HSP90 interplay in malignant cells[J].Trends Pharmacol Sci,2014,35(10):501-509.
22 Bali P,Pranpat M,Bradner J,et al.Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90:a novel basis for antileukemia activity of histone deacetylase inhibitors[J].J Biol Chem,2005,280(29):26729-26734.
23 Robinson DR,Wu YM,Vats P,et al.Activating ESR1 mutationsinhormone-resistant metastatic breast cancer[J].Nat Genet,2013,45(12):1446-1451.
24 Ring A,Dowsett M.Mechanisms of tamoxifen resistance[J].Endocr Relat Cancer,2004,11(4):643-658.
25 Genest O,Wickner S,Doyle SM,et al.Hsp90 and Hsp70 chaperones:Collaborators in protein remodeling[J].J Biol Chem,2019,294(6):2109-2120.
26 Meng QW,Zhao CH,Xi YH,et al.Enhancement of HER-2 degradation by carbamazepine in breast cancer SKBR-3 cell line[J].Zhonghua Zhong Liu Za Zhi,2006,28(7):503-506.
27 Modi S,Stopeck AT,Gordon MS,et al.Combination of trastuzumab and tanespimycin(17-AAG,KOS-953)is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer:a phase I dose-escalation study[J].J Clin Oncol,2007,25(34):5410-5417.
28 Talaei S,Mellatyar H,Asadi A,et al.Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment[J].Chem Biol Drug Des,2019,93(5):760-786.
29 Canonici A,Qadir Z,Conlon NT,et al.The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells[J].Invest New Drugs,2018,36(4):581-589.
30 Nash K,Hafeez A,Hou S.Hospital-acquired renal insufficiency[J].Am J Kidney Dis,2002,9(5):930-936.
31 Cho TM,Kim JY,Kim YJ,et al.C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition[J].Cancer Lett,2019,447:141-153.
32 Li L,Wang L,You QD,et al.Heat shock protein 90 inhibitors:an update on achievements,challenges,and future directions[J].J Med Chem,2020,63(5):1798-1822.
33 Garg G,Khandelwal A,Blagg BS,et al.Anticancer inhibitors of Hsp90 function:beyond the usual suspects[J].Adv Cancer Res,2016,129:51-88.

[1]	陈嘉一, 白彦灵. 乳腺癌患者体重指数及体位固定方式对保乳术后调强放射治疗摆位误差的影响[J]. 实用肿瘤学杂志, 2022, 36(4): 327-331.
[2]	赵丹妮, 闫石, 蔡莉. 乳腺癌随访和药物副作用管理策略的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 369-373.
[3]	杨子涵, 许守平, 庞达. 乳腺癌发生腋窝外三角组织转移特点与影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(3): 226-232.
[4]	何伟丹, 李志高. FSIP1促进乳腺癌细胞迁移和侵袭并导致患者不良预后[J]. 实用肿瘤学杂志, 2022, 36(3): 233-238.
[5]	刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.
[6]	杨姝娅, 刘文慧, 骆耐香. UCA1在乳腺癌中的研究现状和应用展望[J]. 实用肿瘤学杂志, 2022, 36(3): 263-267.
[7]	刘婉莹, 庞达. 乳腺浸润性微乳头状癌转移机制的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 268-272.
[8]	孙元元, 张苧之, 曹孟儒. 乳腺癌肺转移机制及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(2): 173-177.
[9]	侯建勋, 王洪斌. 外泌体对乳腺癌诊疗一体化影响的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 178-182.
[10]	陈赫, 王秋程, 程文. 自动乳腺超声诊断系统在乳腺癌方面的应用进展[J]. 实用肿瘤学杂志, 2022, 36(2): 193-196.
[11]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[12]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[13]	罗波, 张曲, 郑红梅, 梁新军, 周小妹, 吴新红. SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J]. 实用肿瘤学杂志, 2021, 35(6): 523-528.
[14]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.
[15]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.

热休克蛋白90在乳腺癌发生发展及治疗中的研究进展

Research progress of heat shock protein 90 in the occurrence,development and treatment of breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价